NarumiS, NagasakiK, KiriyaM, et al.Functional variants in a TTTG microsatellite on 15q26.1 cause familial nonautoimmune thyroid abnormalities. Nat Genet, 2024; 56(5):869–876; doi: 10.1038/s41588-024-01735-5
2.
GrasbergerH, DumitrescuAM, LiaoXH, et al.STR mutations on chromosome 15q cause thyrotropin resistance by activating a primate-specific enhancer of MIR7-2/MIR1179. Nat Genet, 2024; 56(5):877–888; doi: 10.1038/s41588-024-01717-7
3.
ChoYW, FuY, HuangCJ, et al.Thyroid hormone-regulated chromatin landscape and transcriptional sensitivity of the pituitary gland. Commun Biol, 2023; 6(1):1253; doi: 10.1038/s42003-023-05546-y
4.
Hidalgo-AlvarezJ, Salas-LuciaF, Vera CruzD, et al.Localized T3 production modifies the transcriptome and promotes the hepatocyte-like lineage in iPSC-derived hepatic organoids. JCI Insight, 2023; 8(23); doi: 10.1172/jci.insight.173780
5.
LiuR, ZhuG, TanJ, et al.Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness. J Natl Cancer Inst, 2024; 116(5):694–701; doi: 10.1093/jnci/djad265
6.
DeBoyEA, NicosiaAM, LiyanarachchiS, et al.Telomere-lengthening germline variants predispose to a syndromic papillary thyroid cancer subtype. Am J Hum Genet, 2024; 111(6):1114–1124; doi: 10.1016/j.ajhg.2024.04.006
7.
YangY, Valdes-RivesSA, LiuQ, et al.Thyroid hormone suppresses medulloblastoma progression through promoting terminal differentiation of tumor cells. Cancer Cell, 2024; 42(8):1434–1449 e1435; doi: 10.1016/j.ccell.2024.07.008
8.
HaEJ, LeeJH, LeeDH, et al.Artificial Intelligence Model Assisting Thyroid Nodule Diagnosis and Management: A Multicenter Diagnostic Study. J Clin Endocrinol Metab, 2024; 109(2):527–535; doi: 10.1210/clinem/dgad503
9.
XieP, ShenL, PengR, et al.Effects of low-dose methotrexate with MMI in patients with Graves’ disease: Results of a randomized clinical trial. J Clin Endocrinol Metab, 2024; doi: 10.1210/clinem/dgae472
10.
HadouxJ, EliseiR, BroseMS, et al;LIBRETTO-531 Trial Investigators. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. N Engl J Med, 2023; 389(20):1851–1861; doi: 10.1056/NEJMoa2309719
11.
JansenHI, DirksNF, HillebrandJJ, et al.Age-Specific reference intervals for thyroid-stimulating hormones and free thyroxine to optimize diagnosis of thyroid disease. Thyroid, 2024; 34(11):1346–1355; doi: 10.1089/thy.2024.0346
12.
LeeWY, WangHC, HuangLE, et al.Diagnostic values of surepath liquid-based cytology versus conventional smear in thyroid aspiration samples: A 13-year experience at a single institution. Diagn Cytopathol, 2024; 52(7):369–376; doi: 10.1002/dc.25319
13.
BojarskyM, BaranJA, HaladaS, et al.Outcomes of ATA low-risk pediatric thyroid cancer patients not treated with radioactive iodine therapy. J Clin Endocrinol Metab, 2023; 108(12):3338–3344; doi: 10.1210/clinem/dgad322
14.
CastellanosLE, ZafereoME, SturgisEM, et al.Pediatric papillary thyroid carcinoma: Outcomes after surgery without adjuvant radioactive iodine. J Clin Endocrinol Metab, 2024; doi: 10.1210/clinem/dgae576
15.
VarnerMW, MeleL, CaseyBM, et al;Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, Bethesda, MD, USA. Progression of gestational subclinical hypothyroidism and hypothyroxinemia to overt hypothyroidism after pregnancy: Pooled analysis of data from two randomized controlled trials. Thyroid, 2024; 34(9):1171–1176; doi: 10.1089/thy.2023.0616
16.
BernardiS, RosolenV, BarboneF, et al.Clinical outcomes of thermal ablation re-treatment of benign thyroid nodules: A multicenter study from the Italian minimally invasive treatments of the thyroid group. Thyroid, 2024; 34(3):360–370; doi: 10.1089/thy.2023.0501
17.
FugazzolaL, DeandreaM, BorgatoS, et al.Radiofrequency ablation is an effective treatment for Bethesda III thyroid nodules without genetic alterations. Eur Thyroid J, 2024; 13(3); doi: 10.1530/ETJ-24-0020
18.
LiX, YanL, XiaoJ, et al.Long-Term Outcomes and Risk Factors of Radiofrequency Ablation for T1N0M0 Papillary Thyroid Carcinoma. JAMA Surg, 2024; 159(1):51–58; doi: 10.1001/jamasurg.2023.5202
19.
LiX, LiY, YanL, et al.Sonographic evolution and pathologic findings of papillary thyroid cancer after radiofrequency ablation: A five-year retrospective cohort study. Thyroid, 2024; 34(1):54–63; doi: 10.1089/thy.2023.0415
20.
SawkaAM, GhaiS, RotsteinL, et al.Decision regret following the choice of surgery or active surveillance for small, low-risk papillary thyroid cancer: A prospective cohort study. Thyroid, 2024; 34(5):626–634; doi: 10.1089/thy.2023.0634
21.
BachK, AnsariP, AnsariH, et al.Health-related quality of life in patients with low-risk differentiated thyroid cancer: A systematic review examining the extent of thyroidectomy. Thyroid, 2024; 34(1):14–25; doi: 10.1089/thy.2023.0328
22.
RameshS, Van Den BergNH, SheahanP. Outcomes of immediate total thyroidectomy in first-side loss of neuromonitoring signal. JAMA Otolaryngol Head Neck Surg, 2024; 150(6):509–516; doi: 10.1001/jamaoto.2024.0698
23.
DevonK, TinckamK, HumarA, et al.Successful deceased donor parathyroid allotransplantation: A novel approach in a patient with severe refractory hypoparathyroidism after thyroidectomy for thyroid cancer. Thyroid, 2024; 34(8):1058–1061; doi: 10.1089/thy.2024.0115
24.
MosteiroL, NguyenTTT, HankeovaS, et al.Notch signaling in thyrocytes is essential for adult thyroid function and mammalian homeostasis. Nat Metab, 2023; 5(12):2094–2110; doi: 10.1038/s42255-023-00937-1
25.
MartinezME, KaraczynA, WuZ, et al.Transgenerational epigenetic self-memory of Dio3 dosage is associated with Meg3 methylation and altered growth trajectories and neonatal hormones. Epigenetics, 2024; 19(1):2376948; doi: 10.1080/15592294.2024.2376948
KimDK, ChoiH, LeeW, et al.Brain hypothyroidism silences the immune response of microglia in Alzheimer’s disease animal model. Sci Adv, 2024; 10(11):eadi1863; doi: 10.1126/sciadv.adi1863
28.
GraffunderAS, BresserAAJ, Fernandez ValloneV, et al.Spatiotemporal expression of thyroid hormone transporter MCT8 and THRA mRNA in human cerebral organoids recapitulating first trimester cortex development. Sci Rep, 2024; 14(1):9355; doi: 10.1038/s41598-024-59533-2
29.
RodriguesJS, ChenloM, BravoSB, et al.dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe. Nat Commun, 2024; 15(1):3736; doi: 10.1038/s41467-024-47751-1
BeckerPC, Guth-SteffensM, LazarowK, et al.Identification of human TRIAC transmembrane transporters. Thyroid, 2024; 34(7):920–930; doi: 10.1089/thy.2023.0592
32.
LinLY, ZhouP, ShiM, et al.A deep learning model for screening computed tomography imaging for thyroid eye disease and compressive optic neuropathy. Ophthalmol Sci, 2024; 4(1):100412; doi: 10.1016/j.xops.2023.100412
33.
PozdeyevN, DigheM, BarrioM, et al.Thyroid cancer polygenic risk score improves classification of thyroid nodules as benign or malignant. J Clin Endocrinol Metab, 2024; 109(2):402–412; doi: 10.1210/clinem/dgad530
34.
JonsdottirB, ClasenJL, VehikK, et al;TEDDY Study Group. Early appearance of thyroid autoimmunity in children followed from birth for type 1 diabetes risk. J Clin Endocrinol Metab, 2024; doi: 10.1210/clinem/dgae478
35.
DouglasRS, CouchS, WesterST, et al.Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab, 2023; 109(1):25–35; doi: 10.1210/clinem/dgad637
36.
PałygaI, RumianM, KoselA, et al.The frequency of differentiated thyroid cancer recurrence in 2302 patients with excellent response to primary therapy. J Clin Endocrinol Metab, 2024; 109(2):e569–e578; doi: 10.1210/clinem/dgad571
37.
TaharaM, TakamiH, ItoY, et al.A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer. Thyroid, 2024; 34(5):566–574; doi: 10.1089/thy.2023.0553
38.
BiondiB, PucciM, PontieriG, et al.Preliminary results of a double-blind randomized controlled trial evaluating the cardiometabolic effects of levothyroxine and liothyronine compared to levothyroxine with placebo in athyreotic low-risk thyroid cancer patients. Thyroid, 2023; 33(12):1402–1413; doi: 10.1089/thy.2023.0135
39.
WangW, ZhangX, GaoJ, et al.Effects of levothyroxine in subclinical hypothyroidism and heart failure with reduced ejection fraction: An open-label randomized trial. Cell Rep Med, 2024; 5(4):101473; doi: 10.1016/j.xcrm.2024.101473
40.
Cavnar HelvaciB, PolatSB, BalsakBT, et al.Effect of music therapy on pain during thyroid fine needle aspiration biopsy; A randomized controlled clinical trial. Endocr Pract, 2024; 30(6):521–527; doi: 10.1016/j.eprac.2024.03.008
41.
RaghunathanR, LongstaffXR, HughesEG, et al.Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hurthle cell cytology. Surgery, 2024; 175(1):221–227; doi: 10.1016/j.surg.2023.05.046
42.
BaranJA, HaladaS, BauerAJ, et al.Thyroid ultrasound screening in childhood cancer survivors following radiotherapy. Horm Res Paediatr, 2024; 97(3):243–253; doi: 10.1159/000531241
43.
Cohen-SelaE, BrenerA, RavivO, et al.Outcomes in maternal graves’ disease: A population-based mother-infant dyad cohort study. Thyroid, 2024; 34(1):123–133; doi: 10.1089/thy.2023.0291
44.
XiaoWC, LiX, ShanR, et al.Pregnancy and progression of differentiated thyroid cancer: A propensity score-matched retrospective cohort study. J Clin Endocrinol Metab, 2024; 109(3):837–843; doi: 10.1210/clinem/dgad557
